Related Experiment Videos
[Angiogenesis, lymphangiogenesis, and tumor progression]
1Klinik für Gynäkologie und Geburtshilfe, Georg-August-Universität Göttingen. thomas.hawighorst@med.uni-goettingen.de
Zentralblatt Fur Gynakologie
|June 11, 2003
Summary
Thrombospondins (TSP)-1 and TSP-2 inhibit tumor progression but not malignant conversion. Angiogenesis inhibitors may be best for early tumor stages and combined with lymphangiogenesis inhibitors.
Area of Science:
- Oncology and Molecular Biology
- Tumor Microenvironment Research
Context:
- Angiogenesis is crucial for tumor growth and metastasis, regulated by a balance of pro-angiogenic and anti-angiogenic factors.
- The 'angiogenic switch' precedes other malignant tumor traits, driven by shifts in angiogenic regulators.
- The lymphatic system plays an active role in metastasis, with lymphangiogenesis inhibitors still under investigation.
Purpose:
- To review the role of thrombospondin-1 (TSP-1) and TSP-2 as endogenous angiogenesis inhibitors in tumor development.
- To explore the impact of angiogenesis inhibitors on tumor progression and the conversion of premalignant to malignant tumors.
- To assess the potential effects of angiogenesis inhibitors on lymphangiogenesis and their implications for cancer therapy.
Summary:
- Thrombospondin-1 (TSP-1) and TSP-2 are potent endogenous inhibitors of angiogenesis that impact tumor progression.
- Angiogenesis inhibitors effectively target tumor progression but do not prevent the transition from premalignant to malignant states.
- These inhibitors show selective effects on blood vessel formation, with limited impact on lymphatic vessel development.
Impact:
- Angiogenesis inhibitors may be most effective when used in early stages of tumor progression.
- Combining angiogenesis inhibitors with specific lymphangiogenesis inhibitors could enhance therapeutic efficacy.
- Findings guide the future development and clinical application of angiogenesis-based cancer therapies.